RA Capital Management L.P. bought a new position in shares of Metsera Inc. (NASDAQ:MTSR - Free Report) in the first quarter, according to the company in its most recent filing with the SEC. The fund bought 675,525 shares of the company's stock, valued at approximately $18,388,000. RA Capital Management L.P. owned 0.64% of Metsera as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Alphabet Inc. acquired a new position in Metsera during the 1st quarter worth approximately $135,059,000. T. Rowe Price Investment Management Inc. acquired a new position in Metsera during the 1st quarter worth approximately $78,748,000. Jennison Associates LLC acquired a new position in Metsera during the 1st quarter worth approximately $9,679,000. Charles Schwab Investment Management Inc. acquired a new position in Metsera during the 1st quarter worth approximately $3,410,000. Finally, TD Asset Management Inc acquired a new position in Metsera during the 1st quarter worth approximately $2,091,000.
Analysts Set New Price Targets
Several research firms recently commented on MTSR. Guggenheim boosted their price target on Metsera from $56.00 to $62.00 and gave the stock a "buy" rating in a research report on Tuesday, June 10th. Bank of America upped their target price on Metsera from $45.00 to $50.00 and gave the company a "buy" rating in a research report on Thursday, August 28th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Metsera in a research report on Wednesday. Wall Street Zen raised Metsera from a "sell" rating to a "hold" rating in a research report on Saturday, August 30th. Finally, Wells Fargo & Company started coverage on Metsera in a research report on Friday, June 20th. They issued an "overweight" rating and a $65.00 target price on the stock. Five analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $59.00.
View Our Latest Report on MTSR
Metsera Stock Performance
Shares of MTSR stock traded down $0.42 on Friday, hitting $35.87. 1,520,674 shares of the stock traded hands, compared to its average volume of 1,208,677. Metsera Inc. has a 1-year low of $12.30 and a 1-year high of $47.40. The company's fifty day moving average is $34.73 and its 200 day moving average is $28.67.
Metsera (NASDAQ:MTSR - Get Free Report) last issued its quarterly earnings data on Monday, July 28th. The company reported ($0.66) EPS for the quarter.
Metsera Profile
(
Free Report)
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Read More
Before you consider Metsera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Metsera wasn't on the list.
While Metsera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
